Zhuhai Shine-On Biopharmaceutical

Zhuhai Shine-On Biopharmaceutical is a clinical-stage biotechnology company based in Zhuhai, China, specializing in the development of long-acting protein and peptide therapeutics. The company utilizes its proprietary Shine-On platform to engineer cytokines and hormones with optimized pharmacokinetic profiles, aiming to improve efficacy and reduce toxicity. Its lead candidate, SN101, is a long-acting interleukin-15 (IL-15) fusion protein currently in Phase 1 clinical trials for the treatment of advanced solid tumors. Shine-On's pipeline also includes next-generation immunotherapies such as long-acting IL-21 and IL-7, as well as multi-target agonists for metabolic disorders like diabetes and obesity.